Voyager Therapeutics (NASDAQ:VYGR) Lowered to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a research report released on Saturday morning, Zacks.com reports.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other research analysts also recently issued research reports about the company. Wedbush reissued an outperform rating on shares of Voyager Therapeutics in a research note on Wednesday. Morgan Stanley lowered their target price on Voyager Therapeutics from $28.00 to $26.00 and set an equal weight rating for the company in a research note on Friday, October 11th. ValuEngine downgraded Voyager Therapeutics from a hold rating to a sell rating in a research note on Friday. BidaskClub downgraded Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 27th. Finally, Cowen reaffirmed a buy rating on shares of Voyager Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $27.71.

VYGR stock traded up $0.38 during midday trading on Friday, reaching $14.86. 263,700 shares of the company were exchanged, compared to its average volume of 451,389. The firm has a market capitalization of $548.84 million, a price-to-earnings ratio of -5.40 and a beta of 2.58. Voyager Therapeutics has a one year low of $7.76 and a one year high of $28.79. The business has a 50-day moving average price of $15.86 and a two-hundred day moving average price of $20.84.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.42. The firm had revenue of $20.43 million during the quarter, compared to the consensus estimate of $3.94 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. On average, research analysts expect that Voyager Therapeutics will post -1.95 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $27,000. Allianz Asset Management GmbH increased its position in Voyager Therapeutics by 16.5% during the 2nd quarter. Allianz Asset Management GmbH now owns 93,948 shares of the company’s stock valued at $2,054,000 after purchasing an additional 13,339 shares during the period. HM Payson & Co. acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $63,000. Bailard Inc. acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $1,116,000. Finally, JPMorgan Chase & Co. increased its position in Voyager Therapeutics by 28.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after purchasing an additional 71,451 shares during the period. 78.63% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Recommended Story: Trade War

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.